Joint Hypermobility, Autonomic Dysfunction, Gastrointestinal Dysfunction, and Autoimmune Markers: Clinical Associations and Response to Intravenous Immunoglobulin Therapy
Authors:
- Pankaj J. PasrichaPPPankaj J. Pasricha
- Megan McKnightMMMegan McKnight
- Luisa VillatoroLVLuisa Villatoro
- Guillermo BarahonaGBGuillermo Barahona
- Jeffrey BrinkerJBJeffrey Brinker
- Ken HuiKHKen Hui
- Michael PolydefkisMPMichael Polydefkis
- Robert BurnsRBRobert Burns
- Zsuzsanna H. McMahanZMZsuzsanna H. McMahan
- Neda GouldNGNeda Gould
- Brent GoodmanBGBrent Goodman
- Joseph HentzJHJoseph Hentz
Open Access
- 24 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (11) , 2298-2306
Abstract
INTRODUCTION: We examined autoimmunity markers (AIM) and autonomic dysfunction in patients with chronic neurogastroenterological symptoms and their relationship to joint hypermobility/hypermobility spectrum disorder (JH/HSD). METHODS: AIM positivity was defined as a diagnosis of known autoimmune/autoinflammatory disorder with at least 1 positive seromarker of autoimmunity or at least 2 positive seromarkers by themselves. Three cohorts were studied: (i) retrospective (n = 300), (ii) prospective validation cohort (n = 133), and (iii) treatment cohort (n = 40), administered open-label intravenous immunoglobulin (IVIG). RESULTS: AIM positivity was found in 40% and 29% of the retrospective and prospective cohorts, the majority of whom (71% and 69%, respectively) had autoinflammatory disorder. Significantly more patients with AIM had elevations of C-reactive protein (31% vs 15%, P < 0.001) along with an increased proportion of cardiovascular autonomic dysfunction (48% vs 29%; P < 0.001), small fiber neuropathy (20% vs 9%; P = 0.002), and HLADQ8 positivity (24% vs 13%, P = 0.01). Patients with JH/HSD were more likely to have AIM (43% vs 15%, P = 0.001) along with more severe autonomic and gastrointestinal (GI) symptom scores. IVIG treatment was associated with robust improvement in pain, GI, and autonomic symptoms, but adverse events were experienced by 62% of patients. DISCUSSION: Autoimmune markers and autonomic dysfunction are common in patients with unexplained GI symptoms, especially in those with JH/HSD. Many patients seem to respond to IVIG treatment, but this needs to be confirmed by controlled trials. These results highlight the need for vigilance for autoimmune and autonomic factors and JH/HSD in patients with neurogastroenterological disorders. Clinicaltrials.gov, NCT04859829.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- Microbiome and Its Role in Irritable Bowel SyndromeDigestive Diseases and Sciences, 2020
- Pediatric Intestinal Pseudo-obstruction in the Era of Genetic SequencingCurrent Gastroenterology Reports, 2019
- Cryptogenic small‐fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptor‐3Muscle & Nerve, 2019
- A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunityRheumatology International, 2017
- Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome Type III and Ehlers–Danlos syndrome hypermobility type): Clinical description and natural historyAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2017
- Gastrointestinal and nutritional issues in joint hypermobility syndrome/ehlers–danlos syndrome, hypermobility typeAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2015
- The spectrum of autoimmune autonomic neuropathiesAnnals of Neurology, 2003
- Analysis of Families at Risk for Insulin-Dependent Diabetes Mellitus Reveals that HLA Antigens Influence Progression to Clinical DiseaseMolecular Medicine, 1995
- Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinomaGastroenterology, 1991
- Measurement of health statusControlled Clinical Trials, 1989